grant
Project 2: Inter-Relationship of Disparities, the Microbiome, Innate Immune System and Immunotherapy Response in Endometrial Cancer
Organization UNIV OF NORTH CAROLINA CHAPEL HILLLocation CHAPEL HILL, UNITED STATESPosted 4 Sept 2025Deadline 31 Jul 2030
NIHUS FederalResearch GrantFY2025AffectAntigen-Presenting CellsAntioncogene Protein p53ApoptosisApoptosis PathwayBiological MarkersBiologyBlackBlack raceCancer PatientCancer TreatmentCancersCaucasian FemalesCaucasian WomenCell BodyCellsCellular Tumor Antigen P53Chemotactic CytokinesClinicalClinical Treatment MoabClinical TrialsDataDevelopmentDisease OutcomeDisparateDisparitiesDisparityDoseDrug KineticsDrugsEndocrine systemEndocrine/Metabolic Organ SystemEndometrial CancerEndometrial CarcinomaEndometrium CancerEndometrium CarcinomaFutureGEM modelGEMM modelGI microbiomeGI microbiotaGastrointestinal microbiotaGenetically Engineered MouseGerm-FreeHomologous Chemotactic CytokinesHormonal SystemImmuneImmune TargetingImmune mediated therapyImmune responseImmune systemImmunesImmunologic FactorsImmunological FactorsImmunologically Directed TherapyImmunomodulationImmunotherapeutic agentImmunotherapyInnate Immune SystemIntercrinesInterventionMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMeasurableMeasuresMediatingMediatorMedicationMetabolicMetabolic/Endocrine Body SystemMiceMice MammalsMonoclonal AntibodiesMurineMusMutateNorth CarolinaObesityOncoprotein p53OutcomeP53PD 1PD-1PD-1 antibody therapyPD-1 therapyPD1PD1 antibody therapyPD1 based treatmentParaffinParaffin waxes and Hydrocarbon waxesPathway interactionsPatientsPhagocytosisPharmaceutical PreparationsPharmacokineticsPhosphoprotein P53Phosphoprotein pp53Population StudyPre-Clinical ModelPreclinical ModelsProgrammed Cell DeathProspective StudiesProtein TP53Public HealthRNA SeqRNA sequencingRNAseqRaceRacesResistanceRiskSIS cytokinesStudy modelsSurvival RateSystemTP53TP53 geneTRP53TimeTumor Protein p53Tumor Protein p53 GeneUpregulationWhite FemalesWhite WomenWomanWorkaPD-1 therapyaPD-1 treatmentaPD1 therapyaPD1 treatmentaccessory celladiposityanti-PD-1 therapyanti-PD-1 treatmentanti-PD1 therapyanti-PD1 treatmentanti-cancer therapyanti-programmed cell death 1 therapyanti-programmed cell death protein 1 therapybio-markersbiologic markerbiomarkerblack femaleblack patientblack womencancer disparitycancer health disparitycancer progressioncancer therapycancer-directed therapycancer-related health disparitycheck point blockadecheckpoint blockadechemoattractant cytokinechemokinecorpulencedevelopmentaldiet-associated obesitydiet-induced obesitydiet-related obesitydigestive tract microbiomedisparities affecting femalesdisparities affecting womendisparities among femalesdisparities among womendisparities facing womendisparities impacting womendisparities in femalesdisparities in womendisparity in cancerdrug/agentdysbacteriosisdysbiosisdysbioticendocrine gland/systementeric microbial communityenteric microbiomeenteric microbiotaexpression subtypesfecal microbial transplantationfecal microbiome transplantationfecal microbiota transplantfecal microbiota transplantationfecal samplefecal transplantfecal transplantationfemale disparitiesgastrointestinal microbial floragastrointestinal microbiomegenetically engineered mouse modelgenetically engineered murine modelgut communitygut floragut microbe communitygut microbial communitygut microbial compositiongut microbial consortiagut microbiomegut microbiotagut microbioticgut microfloragut-associated microbiomehost responseimmune check point blockadeimmune checkpoint blockadeimmune drugsimmune modulationimmune regulationimmune system functionimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmuno therapyimmunologic reactivity controlimmunologic substanceimmunologic therapeuticsimmunological substanceimmunomodulatoryimmunoregulationimmunoregulatoryimmunoresponseimmunotherapeuticsimmunotherapy agentimprovedimproved outcomeinhibitorinhibitor druginhibitor therapeuticinhibitor therapyintestinal biomeintestinal floraintestinal microbiomeintestinal microbiotaintestinal microfloraintestinal tract microfloramAbsmalignancymicrobialmicrobial compositionmicrobial consortiamicrobial floramicrobial imbalancemicrobiomemicrobiotamicrobiota patternsmicrobiota profilesmicrobiota signaturemicrofloramolecular sub-typesmolecular subsetsmolecular subtypesmonoclonal Absmortalitymouse modelmultispecies consortiamurine modelneoplasm progressionneoplasm/cancerneoplastic progressionobese patientsp53 Antigenp53 Genesp53 Tumor Suppressorpathwaypatients with obesitypopulation-based studypopulation-level studyprogrammed cell death 1programmed cell death protein 1programmed cell death protein 1 therapyprogrammed death 1prospectiveprotein p53racialracial backgroundracial originresistantresponseresponse to therapyresponse to treatmentsle2small moleculesocial factorsstandard of carestool samplestool specimenstudies of populationsstudy of the populationsurvival outcomesystemic lupus erythematosus susceptibility 2therapeutic responsetherapy optimizationtherapy responsetranscriptome sequencingtranscriptomic sequencingtranslational studytreatment optimizationtreatment responsetreatment responsivenesstumortumor growthtumor microbiometumor microbiotatumor progressiontumor-associated microbiometumor-associated microbiotauptakewomen's disparities
Description preview
ABSTRACT – PROJECT 2
Endometrial cancer (EC) outcomes are among the most disparate in the US, with Black women suffering a much
lower 5-year survival rate than White women. Reasons for this are unclear but likely include an inter-relationship
between measurable social factors and biology, including potentially differences in the microbiome and…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click